(Total Views: 534)
Posted On: 12/31/2019 1:20:19 PM
Post# of 151532
Re: LaundryMoney #14005
Good list of highlights, but I wanted to add a few more:
NP said "killing of cancer cells".....I need to listen again, but sounded like stopping CCR5 actually kills some of the cancer cells!
Both clinical and CMC portions of the BLA will be filed in January.
1st TNBC patient had 20% reduction in tumor size after just a few weeks. This reduction does not happen with early Carboplatin treatment.
M-i-L could barely move before leronlimab. She flew and they went on a cruise recently.
25-30 patients contacted company for expanded access after stunning cancer results….sounded like they were in the screening process. Did not mention results on TNBC trial patient screening…..but I hope we will hear something soon though.
Funding plan is to let warrants fund us. No mention of TO or anything, but if warrants are currently being exercised and BLA and cancer BTD happen soon and bump us higher I would imagine this only helps them to get exercised faster.
NASH – leronlimab stopped fatty liver deposits by 90%. NASH is an estimated $26B US market. In discussions with large pharma in regards to NASH partnership…..threw in cancer partnership also!
NP said "killing of cancer cells".....I need to listen again, but sounded like stopping CCR5 actually kills some of the cancer cells!
Both clinical and CMC portions of the BLA will be filed in January.
1st TNBC patient had 20% reduction in tumor size after just a few weeks. This reduction does not happen with early Carboplatin treatment.
M-i-L could barely move before leronlimab. She flew and they went on a cruise recently.
25-30 patients contacted company for expanded access after stunning cancer results….sounded like they were in the screening process. Did not mention results on TNBC trial patient screening…..but I hope we will hear something soon though.
Funding plan is to let warrants fund us. No mention of TO or anything, but if warrants are currently being exercised and BLA and cancer BTD happen soon and bump us higher I would imagine this only helps them to get exercised faster.
NASH – leronlimab stopped fatty liver deposits by 90%. NASH is an estimated $26B US market. In discussions with large pharma in regards to NASH partnership…..threw in cancer partnership also!
(1)
(0)
Please do your own due diligence. All my posts and comments are not to be considered investment advice.
Scroll down for more posts ▼
